Handelsbanken Fonder
RPRX icon

Handelsbanken Fonder’s Royalty Pharma RPRX Stock Holding History

Handelsbanken Fonder’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.2M Buy
557,028
+121,761
+28% +$6.34M 0.09% 192
2026
Q1 		$20.9M Buy
435,267
+119,581
+38% +$5.24M 0.07% 228
2025
Q4 		$12.2M Buy
315,686
+56,061
+22% +$2.14M 0.04% 360
2025
Q3 		$9.16M Buy
259,625
+6,417
+3% +$232K 0.03% 386
2025
Q2 		$9.12M Sell
253,208
-180,280
-42% -$5.97M 0.03% 361
2025
Q1 		$13.5M Sell
433,488
-26,695
-6% -$846K 0.06% 292
2024
Q4 		$11.7M Sell
460,183
-261,144
-36% -$6.92M 0.04% 331
2024
Q3 		$20.4M Buy
721,327
+6,298
+0.9% +$174K 0.08% 228
2024
Q2 		$18.9M Buy
715,029
+33,728
+5% +$935K 0.08% 220
2024
Q1 		$20.7M Sell
681,301
-210,617
-24% -$6.21M 0.09% 213
2023
Q4 		$25.1M Sell
891,918
-39,718
-4% -$1.09M 0.12% 181
2023
Q3 		$25.3M Buy
931,636
+140,300
+18% +$4.17M 0.14% 165
2023
Q2 		$24.3M Buy
791,336
+85,802
+12% +$2.91M 0.13% 175
2023
Q1 		$25.4M Buy
705,534
+95,081
+16% +$3.53M 0.15% 167
2022
Q4 		$24.1M Buy
610,453
+471,553
+339% +$19.7M 0.15% 165
2022
Q3 		$5.58M Buy
138,900
+89,700
+182% +$3.83M 0.04% 388
2022
Q2 		$2.07M Buy
49,200
+6,600
+15% +$271K 0.01% 526
2022
Q1 		$1.66M Buy
42,600
+8,800
+26% +$346K 0.01% 623
2021
Q4 		$1.35M Hold
33,800
– – 0.01% 758
2021
Q3 		$1.22M Buy
33,800
+18,900
+127% +$734K 0.01% 797
2021
Q2 		$459K Buy
+14,900
New +$634K ﹤0.01% 1437
2021
Q1 		– Sell
-8,144
Closed -$408K – 1585
2020
Q4 		$408K Buy
+8,144
New +$346K ﹤0.01% 1265

Other funds holding RPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
KMC
Kirr Marbach & Co Columbus, Indiana $594M AUM 34% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CI
Cooper Investors Melbourne, Victoria, Australia $218M AUM 0.39% 1-Year Est. Return
KC
Kepler Cheuvreux Nyon $1.75B AUM 37.37% 1-Year Est. Return
BG
BDF Gestion Paris, France $747M AUM 47.35% 1-Year Est. Return
FIC
FCG Investment Company Germantown, Tennessee $289M AUM

Handelsbanken Fonder's RPRX Position: Q2 2026 in Review

Handelsbanken Fonder increased its Royalty Pharma (RPRX) stake by 28% in Q2 2026, buying an estimated $6.34M and bringing the position to 557,028 shares worth $31.2M. The position accounts for 0.09% of the portfolio, ranked #192.

Handelsbanken Fonder first reported a position in RPRX in Q4 2020 and has held it in 22 quarters since. 54 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Handelsbanken Fonder held 557,028 shares of Royalty Pharma worth $31.2M as of Q2 2026.
  • Handelsbanken Fonder bought 121,761 Royalty Pharma shares in Q2 2026, an estimated $6.34M.
  • Royalty Pharma made up 0.09% of Handelsbanken Fonder's portfolio in Q2 2026, its #192 holding.
  • Handelsbanken Fonder first reported a position in Royalty Pharma in Q4 2020 and has held it in 22 quarters since.
  • 54 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.